Lumitin (conbercept) / Chengdu Kanghong Pharma - LARVOL DELTA

Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. (PubMed, J Comp Eff Res) - "Faricimab, administered according to a personalized treatment interval regimen following four initial monthly injections, was compared with aflibercept (every 8 weeks) and with ranibizumab and conbercept (both following a pro-re nata dosing regimen). Sensitivity analyses confirmed the robustness of these results, consistently demonstrating faricimab as a dominant and cost-effective treatment option for DME. This first Chinese cost-effectiveness study of faricimab for DME shows it enhances visual outcomes and reduces costs, supporting its adoption and providing evidence for healthcare decision-making on reimbursement and resource allocation."

HEOR • Journal • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives. (PubMed, BMC Public Health) - No abstract available

Journal • Real-world evidence • Reimbursement • US reimbursement • Cardiovascular

Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant Therapy for Macular Edema: A Randomized Controlled Trial. (PubMed, Drug Des Devel Ther) - "To compare the efficacy and safety of intravitreal conbercept monotherapy versus conbercept combined with dexamethasone implant in eyes with macular edema (ME)...OCT biomarkers display prognostic value. HE is associated with poor visual prognosis."

Clinical • Journal • Cardiovascular • Diabetic Retinopathy • Glaucoma • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity. (PubMed, Front Med (Lausanne)) - "A lower PMA at initial treatment and Zone I ROP were identified as significant risk factors for reactivation. Infants with these characteristics require closer and more prolonged follow-up after anti-VEGF therapy."

Journal • Retinal Disorders • Retinopathy of Prematurity

Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: a systematic review and network meta-analysis. (PubMed, Surv Ophthalmol) - "Dose-response analysis revealed 0.25mg conbercept balanced efficacy (82.70% inactivity) and safety (3.84% AEs), while 0.3mg showed peak efficacy (90.7%) but limited safety data. Higher doses reduced recurrence (22.97% at 0.15mg vs 17.00% at 0.25mg)."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Retinal Disorders • Retinopathy of Prematurity

Comparing the Efficacy and Safety of Intravitreal Dexamethasone Implant Versus Conbercept in Refractory Diabetic Macular Edema: A Retrospective Cohort Study. (PubMed, Photodiagnosis Photodyn Ther) - "DEX implants provide better short-term efficacy but with higher risks, while conbercept offers safer outcomes for refractory DME."

Journal • Retrospective data • Cardiovascular • Cataract • Diabetic Macular Edema • Glaucoma • Ophthalmology

Effect of conbercept combined with dexamethasone implantation on Macular Thickness, Visual Function, Retinal Perfusion, and Inflammatory Markers in Patients with Diabetic Macular Edema: A Prospective Controlled Study. (PubMed, Photodiagnosis Photodyn Ther) - "Conbercept Plus Dexamethasone provides superior long-term structural, functional, and microvascular benefits compared with conventional therapy, likely mediated by enhanced resolution of inflammation. CMT strongly predicts visual outcomes, supporting its use as a primary surrogate marker in clinical management of DME."

Journal • Diabetes • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology • CXCL8 • IL10 • IL6

Compare Combined Use of Anti-VEGF Drugs During or After PPV for Diabetic Macular Edema Guided by MIOCT. (PubMed, Retina) - "In PDR patients with MIOCT-identified DME during vitrectomy, immediate anti-VEGF treatment provides superior BCVA and CMT improvements compared to delayed treatment, with conbercept demonstrating better efficacy."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Application of conbercept injection in anti-neovascular glaucoma combined trabeculectomy (ChiCTR) - P4 | N=60 | Completed | Sponsor: Department of Ophthalmology, the Second Affiliated Hospital of Harbin Medical University; The second affiliated hospital of Harbin medical university

New P4 trial • Glaucoma • Ophthalmology

Vitrectomy With or Without Conbercept for Proliferative Diabetic Retinopathy with Fibrovascular Membranes: A Prospective Randomized Controlled Trial (ChiCTR) - P=N/A | N=160 | Not yet recruiting | Sponsor: Tianjin Medical University General Hospital; Tianjin Medical University General Hospital

New trial • Diabetic Retinopathy • Retinal Disorders

Acute Diffuse Retinal Hemorrhage Following Intravitreal Conbercept Injection: A Case Report and Mechanistic Analysis. (PubMed, J Vis Exp) - "The patient had undergone pan-retinal photocoagulation in both eyes and received 11 bilateral IVC injections (0.5 mg/0.05 mL per eye) over a 12-month period. This report examines the underlying mechanisms, clinical course, and management, emphasizing the importance of personalized strategies for complex cases."

Journal • Cardiovascular • Diabetes • Diabetic Retinopathy • Hematological Disorders • Hypertension • Metabolic Disorders • Retinal Disorders

Evaluation of Ahmed glaucoma valve versus Ex-PRESS shunt implantation with conbercept therapy in neovascular glaucoma. (PubMed, Medicine (Baltimore)) - "Both AGV and Ex-PRESS implantation combined with conbercept provide effective and safe short-term management for NVG. Over a 1-year period, AGV implantation demonstrated better IOP control, indicating its potential benefit for long-term outcomes in NVG treatment."

Clinical • Journal • Glaucoma • Ophthalmology

Preoperative intravitreal injection of conbercept improves the efficacy of neovascular glaucoma surgery. (PubMed, Am J Transl Res) - "Preoperative intravitreal conbercept injection significantly improves NVI, visual acuity, and intraocular pressure control in patients with NVG, reduces the incidence of complications, and demonstrates both significant efficacy and good safety."

Journal • Glaucoma • Ophthalmology • Pain

Novel OCT Angiography Parameters for Analyzing Microvascular Changes in Proliferative Diabetic Retinopathy After Intravitreal Conbercept Loading Injections. (PubMed, Photodiagnosis Photodyn Ther) - "Novel OCTA parameters revealed that IVC loading injections can improve retinal microvasculature in PDR patients. However, using these novel parameters for follow-up and treatment assessment remains challenging under varying image processing conditions."

Journal • Diabetic Retinopathy • Retinal Disorders

Intravitreal conbercept plus traditional Chinese medicine for diabetic macular edema: A systematic review and meta-analysis. (PubMed, Pak J Pharm Sci) - "IVC combined with TCM may provide additional therapeutic benefits for patients with DME without increasing safety risks. Nevertheless, high-quality, large-scale, multicenter RCTs are still required to further confirm these findings."

Clinical • Journal • Retrospective data • Review • Diabetic Macular Edema • Ophthalmology

Investigating Predictors of Retreatment following Initial Antivascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. (PubMed, J Curr Ophthalmol) - "Among children treated with anti-VEGF agents, the highest IR occurred with intravitreal ranibizumab (IVR, 0.25 mg) (27%, 95% CI: 19%-35%) and intravitreal aflibercept (IVA, 0.4 mg) (27%, 95% CI: 6%-47%), followed by intravitreal conbercept (IVC, 0.25 mg) (16%, 95% CI: 13%-20%). The lowest IR was observed in children treated with intravitreal bevacizumab (IVB, 0.625 mg) (11%, 95% CI: 7%-14%)...While anti-VEGF therapy is effective for ROP treatment, there are significant differences in IR among different agents. IVB treatment appears to yield the most consistent results compared to other agents."

Journal • Retrospective data • Review • Retinal Disorders • Retinopathy of Prematurity

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review. (PubMed, Value Health Reg Issues) - "Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. (PubMed, Eur J Pharmacol) - "Aflibercept and conbercept may be preferred when anatomical outcomes are prioritized, whereas faricimab's extended dosing interval could benefit treatment-adherent populations. The superior safety profile of aflibercept 2 mg warrants consideration in risk averse patients. These differential effects support personalized therapeutic decision-making."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Aqueous Humor Proteome in RVO-Associated Macular Edema: Analysis during Three Consecutive Conbercept Treatments. (PubMed, ACS Omega) - "This exploratory proteomic analysis identified distinct pathway alterations in early RVO pathogenesismetabolic in BRVO and inflammatory in CRVOand common treatment-related changes: plasma kallikrein was downregulated, while desmocollin-3 was up-regulated."

Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • FBLN1 • FSTL1

Vitrectomy with Subretinal Tenecteplase and Intravitreal Conbercept for Submacular Hemorrhage: A Prospective Interventional Study. (PubMed, Retina) - "The present technique for treatment-naïve spontaneous SMH, in combination with subretinal TNK-tPA injection, intravitreal conbercept administration, and C3F8 gas tamponade, demonstrated potential for visual improvement in eyes treated within 30 days of SMH onset."

Journal • Age-related Macular Degeneration • Cardiovascular • Hematological Disorders

Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China (ISPOR-EU 2025) - "However, calculation of these drugs' societal value remains unexplored. The societal value of 4 therapies for the diseases from 2024 to 2033 was estimated, which are currently included in the National Reimbursement Drug List (NRDL), namely faricimab, aflibercept, ranibizumab, and conbercept. Intravitreal injections demonstrate great societal value and significant improvement in quality of life for patients with retinal vascular diseases. Our findings further provide a new perspective for the NRDL to assess innovative drugs' value, underscoring the importance of multiple dimensions in the assessment of the value of innovative medication."

Reimbursement • US reimbursement • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Spontaneous remission of retinal capillary macroaneurysm: case report. (PubMed, Front Med (Lausanne)) - "Although the lesion initially enlarged after three intravitreal injections of conbercept, it eventually resolved spontaneously. This outcome suggested that close observation may be appropriate for RCM patients with stable, good vision if such patients are unwilling or afraid to receive laser treatment."

Journal • Cardiovascular • Hematological Disorders • Retinal Disorders • Retinal Vein Occlusion

Analysis of the Efficacy of Conbercept in Treating Macular Neovascularization of Different nAMD Subtypes Based on OCTA Evaluation (ChiCTR) - P=N/A | N=45 | Not yet recruiting | Sponsor: Nanchong Hospital , Affiliated to Beijing Anzhen Hospital, Capital Medical University; Nanchong Hospital , Affiliated to Beijing Anzhen Hospital, Capi

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A real-world study on the treatment of refractory diabetic macular edema with Conbercept combined with micropulse laser therapy (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University Dezhou Hospital; Qilu Hospital of Shandong University Dezhou Hospital

New trial • Real-world evidence • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

Wide-field OCT angiography-guided precise laser therapy for ischemic branch vein occlusion in anti-VEGF era (ChiCTR) - P=N/A | N=50 | Recruiting | Sponsor: Eye and ENT hospital of Fudan University; Eye and ENT hospital of Fudan University

New trial • Retinal Disorders • Retinal Vein Occlusion